A Phase II Clinical Trial of Pembrolizumab in Subjects with Selec

To evaluate the anti-tumor activity of single agent pembrolizumab (MK-3475) in subjects with a tumor expressing one (or more) of three pre-specified biomarkers. These biomarkers are (1) tumor expression of PD-L1, as assessed by IHC, (2) GEP positive by tumor RNA analysis, and (3) MSI high based on tumor DNA analysis.

April 07, 2016